Search
Publications & Presentationsbreadcrumb separatorPresentationsbreadcrumb separator2006-2011
DDR Menu
Presentations 2006-2011

2011

13th European AIDS Conference/EACS, Belgrade, October 2011

Oral presentations

1 Non-AIDS defining malignancies (NADM) in the D:A:D study: Time trends and predictors of survival. S Worm for the D:A:D study group. presentation

2 Chronic hepatitis C (HCV) infection and chronic kidney disease (CKD) in HIV-infected patients in the EuroSIDA study. L Peters on behalf of the EuroSIDA study. presentation

3 The incidence of serious non-AIDS defining infections in the EuroSIDA cohort. J Reekie on behalf of the EuroSIDA study. presentation

4 Predictors of hepatitis C viremia in co-infected individuals. D Grint, A Phillips on behalf of the EuroSIDA study. presentation

5 Hepatitis delta in HIV-infected individuals in Europe. V Soriano on behalf of the EuroSIDA study.presentation

6 HIV Indicator Diseases across Europe Study (HIDES I): Results from the pilot phase.

7 Mortality Rate, TB Recurrence and Causes of Death in HIV/TB Coinfected Patients: Results from the HIV/TB Collaborative Study. DN Podlekareva, D Grint, A Panteleev, A Rakhmanova, R Miller, M Bruyand, H Furrer, F Post, I Zeltina, A Skrahin, JM Miro, N Obel, E Girardi, MH Losso, J Toibaro, J Caylá, JD Lundgren, O Kirk, HIV/TB Collaboration Study Group. Presentation


ICAAC, September 2011

Poster presentations

1 Renal Failure Related to Broad-spectrum Antibiotics in Critically Ill Patient
ME Johansen, JU Jensen, , L Hein, B Lundgren, M Bestle, T Mohr, MH Andersen, KJ Thornberg, J Loken, M Steensen, Z Fox, H Tousi, P Soe-Jensen, AO Lauritsen, D Strange6, N Reiter, K Thormar, P Fjeldborg, KM Larsen, NE Drenck, L Ryom, C Ostergaard, J Kjaer, J Grarup, JD Lundgren. poster (82 kb)

2 Candida Infections Related to Broad-spectrum Antibiotics in Critically Ill Patients
JU Jensen, K Reinholdt, L Hein6, B Lundgren, M Bestle, T Mohr, MH Andersen, J Loken, H Tousi, P Soe-Jensen, AO Lauritsen, D Strange, N Reiter, K Thormar, KM Larsen, NE Drenck, ME Johansen, C Ostergaard, JK Møller, B Olesen, MC Arendrup, J Kjaer, J Grarup, JD Lundgren for the PASS study group. poster (118 kb)

3 Cytomegalovirus and the Drugs Used to Prevent and Treat This Infection as Risk Factors for Longer Term Deterioration of Kidney Function after Solid Organ and Human Stem Cell Transplanantion C da Cunha-Bang, S S Sørensen, M Iversen, H Sengeløv, A Rasmussen, F Gustafsson, Z Fox, J D Lundgren. poster (158 kb)

13th Int. Workshop on Adverse Drug Reactions and Co-morbidities in HIV, Rome, July 2011

Oral presentations

Development of a definition for Rapid Progression (RP) of renal disease in HIV-positive persons. L Ryom, DA Kamara, SW Worm, MJ Ross, P Reiss, CA Fux, P Morlat, O Moranne, O Kirk, C Smith and JD Lundgren for the D:A:D study group. presentation

Int. Workshop on HIV & Hepatitis Virus Drug Resistance & Curative Strategies, June 2011, Los Cabos

Poster presentation

1 Development of a cross European virtual sample repository and HIV resistance database. J Kjær, DK Kristensen, G Beheydt, S Imbrechts, M Rickenbach, I Fanti, F Incardona and A-M Vandamme

9th European Workshop on HIV & Hepatitis – Treatment Strategies & Antiviral Drug Resistance, March 2011, Cyprus

Poster presentation

1 A semi-automated system to query distributed heterogeneous viral databases. G Beheydt, E Schülter, S Imbrechts, A Abecasis, FM Codoñer, D Paraskevis, A Sönnerborg, A-M Vandamme and J Kjær.

18th Conference on Retroviruses and Opportunistic Infections, Boston, February 2011

Poster Presentations

1 Risk of Cause-specific Deaths over Calendar Time and according to Cumulative Exposure to Combination Antiretroviral Therapy (cART).JD Kowalska, A Mocroft, J Reekie, A Phillips, P Reiss, B Ledergerber, J Gatell, A d'Arminio Monforte, JD Lundgren and O Kirk for the EuroSIDA study group. poster (448 KB)

2 Predictors of Virologic Response to Etravirine-based cART Regimens in a Large European Cohort of HIV-infected Patients. A Cozzi-Lepri, R Paredes, A Phillips, J Kjær, A Lazzarin, J van Lunzen, A Karlsson, M Johnson, and J Lundgren for the EuroSIDA study group. poster (141 KB)

3 Kinetics of Platelet Counts following Interruption of ART: Results from the SMART Study. E Zetterberg, J Neuhaus, for SMART/INSIGHT Study Group.

4 HCV Treatment and CD4 Cell Count Decline in HIV/HCV Co-infected Patients: European Cohort Collaboration. C Smit, A d'Arminio, F de Wolf, M Puoti, F Dabis on behalf of the HCV working group of COHERE. poster (99 KB)

2010

2010 National Summit on HIV Diagnosis, Prevention, and Access to Care, Washington DC, November 2010

Poster

1 Overcoming Obstacles to Late Presentation for HIV in Europe. N Dedes, JV Lazarus, T Coenen, A Phillips, M Weait, J Hows, D Raben, JD Lundgren, HIV in Europe Steering Committee Poster

The 10th International Congress on Drug Therapy in HIV Infection, Glasgow, November 2010

Oral

1 Fatal and non-fatal AIDS and non-AIDS events in HIV-1 infected patients with high CD4 counts. J Reekie, J Gatell, I Yust, E Bakowska, A Rachmanova, M Losso, M Krasnov, P Francioli, J Kowalska, A Mocroft for the EuroSIDA study group. Presentation

2 Vitamin D and clinical disease progression n HIV infection: results from the EuroSIDA study. JP Viard, JC Souberbielle, O Kirk, B Knysz, M Losso, J Gatell, C Pedersen, JR Bogner, A Mocroft, JD Lundgren Presentation

3 A pilot study to determine the prevalence of HIV in individuals presenting for care with selected conditions: Preliminary results: the HIV in Europe Indicator Diseases Across Europe Study. A Sönnerborg on behalf of the Indicator Diseases Across Europe Study Group.
Presentation

Posters

1 Changing Antiretrovirals whilst Viral Load <50 copies/ml and Relationship with CD4 Count Changes. A Mocroft, J Reekie, C Katlama, A Lazzarin, M Ristola, H Sambatakou, J Gasiorowski, D Jevtovic, O Kirk and JD Lundgren for the EuroSIDA study group. Poster (80 KB)

2 Haemoglobin and anaemia in the SMART study. A Mocroft, AR Lifson, G Touloumi, J Neuhaus, Z Fox, A Palfreeman, M Vjecha, S Hodder, S De Wit, JD Lundgren, AN Phillips for the INSIGHT SMART study group. Poster (570 KB)

3 A Pilot Study to Determine the Prevalence of HIV in Individuals Presenting for Care with Selected Conditions: Preliminary Results: The HIV in Europe Indicator Diseases Across Europe Study. A Sönnerborg, A Mocroft, JD Lundgren, D Raben, J Gatell, A Vassilenko, V Hadziosmanovic, J Begovac, H Sørensen, M Cusini, N Clumeck, B Gazzard, J Rockstroh, M Zuin, A d'Arminio Monforte on behalf of the HIV Indicator Diseases Across Europe Study Group. Presentation (2 MB)

4 Fatal and Non-fatal AIDS and Non-AIDS Events in HIV-1 Infected Patients with High CD4 Counts According to Viral Load Strata. J Reekie, J Gatell, I Yust, E Bakowska, A Rachmanova, M Losso, M Krasnov, P Francioli, J Kowalska, A Mocroft for the EuroSIDA study group. Poster (99KB)

5 Chronic Kidney Disease in Patients with Normal eGFR at Baseline - Results from EuroSIDA. L Ryom, A Mocroft, P Reiss, B Ledergerber, S De Wit, D Duiculescu, AD Monforte, M Murphy, JD Lundgren, O Kirk for the EuroSIDA study group. Poster (99 KB)

6 Relating Protease Inhibitor Resistance at Time of Virological Failure with Drug Exposure. M Van Luin, WP Bannister, R Paredes, AN Phillip, J Bruun, J Van Lunzen, O Kirk, A d'Arminio Monforte, A Cozzi-Lepri, DM Burger, and the EuroSIDA group. Poster (80 KB)

7 Vitamin D and Clinical Disease Progression in HIV Infection: Results from the EuroSIDA Study. JP Viard, JC Souberbielle, O Kirk, B Knysz, M Losso, J Gatell, C Pedersen, JR Bogner, A Mocroft, JD Lundgren for the EuroSIDA study group. Poster (98 KB)

XVIII International AIDS Conference, Vienna, July 2010

Posters

1 Causes of death in HIV/TB coinfected patients: Results from the HIV/TB collaborative study.A Panteleev, D Podlekareva, W Bannister, V Riekstina, A Rakhmanova, F Post, JM Miro, H Furrer, M Bruyand, RF Miller, E Girardi, M Losso, J Toibaro, J Caylá, N Obel, A Skrahin, N Chentsova, JD Lundgren, A Mocroft, O Kirk, and the HIV/TB study group Poster

2 Disclosure and preceived HIV-related discrimination in Danish dental clinics. M Mansfeld, P Björkman. Poster

3 Overcoming obstacles to late presentation for HIV in Europe. JV Lazarus, D Raben, T Coenen, JD Lundgren, HIV in Europe Steering Committee. Poster

17th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 2010

Oral Presentations

1 Rates of Cardiovascular Disease Following Smoking Cessation in Patients with HIV Infection: Results from the DAD Study. K Petoumenos, S Worm, P Reiss, S De Wit, A d'Arminio Monforte, N Friis-Moller, R Weber, P Mercie, C Pradier, J Lundgren on behalf of the DAD study group.
Presentation

2 Triglycerides and the risk of myocardial infarction in the DAD study. S Worm, A Kamara, W El-Sadr, O Kirk, E Fontas, P Reiss, A Phillips, M Bruyand, A d'Arminio Monforte, M Law, R Weber, J Lundgren, C Sabin on behalf of the DAD study group.
Presentation

3 Chronic kidney disease (CKD) and exposure to antiretroviral drugs (ARVs) in a large cohort with long-term follow-up: the EuroSIDA Study. O Kirk, A Mocroft, P Reiss, S De Wit, D Sedlacek, M Beniowski, J Gatell, A Phillips, B Ledergerber, J Lundgren, for the EuroSIDA study group.
Presentation
Questions and answers

Posters

1 Biomarkers of inflammation and coagulation and risk of non-AIDS death in HIV/Hepatitis coinfected patients in the SMART study. L Peters, J Neuhaus, D Duprez, JD Neaton, R Tracy, MB Klein, A Mocroft, J Rockstroh, G Dore, JD Lundgren; for the INSIGHT SMART study group. poster

2 Predicted effect on transmission of HIV-1 resistance of timing of implementation of viral load monitoring to determine switches from first to second line antiretroviral regimens in resource-limited settings. A Phillips, D Pillay, G Garnett, D Bennett, M Vitoria, V Cambiano, J Lundgren.

2009

EACS Conference 11-14 November 2009 Cologne

Plenary Session

Earlier Recognition of HIV: A Pressing Need
Prof. Jens Lundgren, MD DMSc. Co-chair "HIV IN EUROPE Initiative" steering committee. University of Copenhagen & State University Hospital, Denmark
presentation

Oral

1 Estimating AIDS and non-AIDS related deaths for patients with missing death data in the EuroSIDA cohortJustyna D. Kowalska, Amanda Mocroft, Bruno Ledergerber, Robert Colebunders, Mattie Ristola, Josip Begovac, Helen Sambatakou, Court Pedersen, Jens D. Lundgren, Ole Kirk
presentation

2 Improvements in mortality between 2002-2007 across Europe : Differences between regions of Europe A Mocroft, B Gazzard, A Karlsson, I Karpov, S D Wit, J v Lunzen, C Katlama, K Zilmer, O Kirk, JD Lundgren on behalf of the EuroSIDA study group.
presentation

3 Tuberculosis (TB) among HIV-1 infected patients across Europe: change over time and risk factors Alexej Kruk, Wendy Bannister, Daria Podlekareva, Nelly Chensova, Aza Rakhmanova, Andrzej Horban, Pere Domingo, Jens D Lundgren, Amanda Mocroft, Ole Kirk, for the EuroSIDA Study Group.
presentation

4 Survival and prognostic factors for patients with non-AIDS defining malignancies (NADM) Csaba Kosa, Joanne Reekie, Johannes Bogner, Pierre-Marie Girard, Gerd Fätkenheuer, Antonio Chiesi, Martin Fisher, Frederik Neess-Engsig, Amanda Mocroft, Ole Kirk
presentation

5 Has the uptake of treatment for chronic hepatitis C virus infection (CHC) in HIV-positive patients in Europe changed over time? A. Mocroft, M. Vogel, M. Beniowski, C. Pradier, M. Battegay, D. Jevtovic, V. Soriano, L. Peters, J. Lundgren,J.K. Rockstroh, for the EuroSIDA Study Group.
presentation

6 Health Care Index (HCI) and Outcome following a diagnosis of tuberculosis (TB) O Kirk, A Mocroft, DN Podlekareva, FA Post, V Riekstina, JM Miro, H Furrer, M Bruyand, AM Panteleev, AG Rakhmanova, E Girardi, MH Losso, JJ Toibaro, J Caylá, RF Miller, N Obel, A Skrahina, N Chentsova, JD Lundgren, for the HIV/TB study group.
presentation

7 Epidemiological and virological characteristics of chronic HBV infection in HIV-positive patients in Europe from 1994 - 2006. Martin Vogel, Amanda Mocroft, Lars Peters, Francisco Antunes, Nikolai Kirkby, Stephane De Wit, Antonella d’Arminio Monforte, Robert Flisiak, Jürgen K. Rockstroh, Vincent Soriano for the EuroSIDA Study Group.
presentation

8 CD4 count, viral suppression, prophylaxis and the risk of primary pneumocystis pneumonia in the cart era - the Collaboration of Observational HIV Epidemiological Research Europe (COHERE). Amanda Mocroft, Jose M. Miro, Hansjakob Furrer, for the Opportunistic Infections Working Group.
persentation

9 Mortality rates of elderly HIV-infected adults treated with antiretroviral are closer to general population than in younger patients. Charlotte Lewden on behalf of COHERE.

Posters

1 Dialysis and renal transplantation in HIV-infected patients: a European survey in 2008 A Mocroft, JC Trullas, F Cofan, J Tourret, A Moreno, C Isnard, C Fux, C Katlama, P Reiss, J Lundgren, JM Gatell, O Kirk, JM Miro and the EuroSIDA Investigators.
poster

2 Predictors of having a resistance test following confirmed viral load (VL) failure of cART. ZV Fox, AN Phillips, A Cozzi-Lepri, A d'Arminio Monforte, A Karlsson, A Mocroft, G Kronborg, J Kjaer, B Clotet and JD Lundgren for the EuroSIDA study group.
poster

3 Prevalence of HIV-1 drug resistance over calendar time in EuroSIDA patients receiving antiretroviral therapyWendy Bannister, Alessandro Cozzi-Lepri, Jesper Kjær, Bonaventura Clotet, Adriano Lazzarin, Jean-Paul Viard, Gitte Kronborg, Dan Duiculescu, Marek Beniowski, Ladislav Machala and Andrew Phillips.
poster

4 Presence of drug resistance during the course of treatment in patients who developed virological failure to the three original classes of antiretroviral drug. Frank de Wolf on behalf of COHERE.

5 Viral load outcome after virologic failure of the three original antiretroviral drug classes in 2000-2007. Dominique Costagliola on behalf of COHERE.

6 HIV-related Hodgkin lymphoma in the era of HAART: incidence and survival in a European mulit-cohort study. Julia Bohlius on behalf of COHERE.

47th Annual Meeting of the Infectious Diseases Society of America, Philadelphia, October 2009

Oral

1 Can sequential procalcitonin or neopterin measurements help improve survival in the ICU? J Jensen, B Lundgren, J D Lundgren.

2 Efficacy and safety of Procalcitonin (PCT) guided antimicrobial chemotherapy (AMC) in the intensive care unit (ICU): Final results from a ransomised controlled trial of 1,200 patientsJ Jensen, L Hein, M Bestle, K Thornberg, J Løken, M Steensen, Z Fox, H Tousi, P Søe-Jensen, J Kjær, A Ø Lauritsen, D Strange, P L Petersen, N Reiter, S Hestad, K Thormar, M H Andersen, T Mohr, P Fjeldborg, K M Larsen, N Drenck, C Østergaard, B Lundgren, J Grarup, J Lundgren.

Poster

1 Post-transplant CMV infection (CMVI): Therapeutic and immunological risk factors. C da Cunha-Bang, S Sørensen, M Iversen, H Sengeløv, J Hillingsø, S Mortensen, Z Fox, J Lundgren, The Herpes Virus Transplantation Study Group at the State University Hospital (Rigshospitalet), State University Hospital & Univeristy of Copenhagen, Denmark.
Poster 244 KB.

Frontiers of Retrovirology: Complex retroviruses, retroelements and their hosts, Montpellier, September 2009

Poster

1 A Bioinformatic Approach to Indentify New Potential Resistance Relevant Amino Acid Substitution (AAS) in HIV-1 Protease. CM Frederiksen, J Kjær, A Cozzi-Lepri, Z Fox and JD Lundgren.
Poster (428 KB)

5th European Conference on Clinical and Social Research on AIDS and Drugs, Vilnius, April 2009

Poster

1 A regional comparison of the mode of HIV-1 transmission in patients enrolled in the EuroSIDA study. J Tverland, J Reekie, M Paulsen, A Mocroft, A Vassilenko, V Uzdaviniene, N Zakharova, N Chentcova, M Ellefson, O Kirk for EuroSIDA. Poster 72 KB

7th European Drug Resistance Workshop, Stockholm, March 2009

Poster

1 Predictors of having a resistance test following at least one episode of viral load (VL) failure of cART: data from EuroSIDA. ZV Fox, AN Phillips, A Cozzi-Lepri, A d'Arminio Monforte, A Karlsson, A Mocroft, G Kronborg, J Kjaer, B Clotet and JD Lundgren for EuroSIDA.
Poster 191 KB

16th Conference on Retroviruses and Opportunistic Infections, Montreal, February 2009

Oral Presentations

1Risk of myocardial infarction (MI) in those exposed to specific antiretroviral drugs (ARVs) from the protease (PI), non-nucleoside reverse transcriptase (NNRTI) and nucleos(t)ide reverse transcriptase inhibitor (NRTI) drug classes: the D:A:D Study. JD Lundgren, P Reiss, S W Worm, W El-Sadr, S DeWit, R Weber, A d'Arminio Monforte, O Kirk, E Fontas, F Dabis, M G Law, N Friis-Møller, A N Phillips, C Sabin, on behalf of the D:A:D study group.
Presentation 115 KB

2 High hepatitis C viremia is associated with an increased risk for mortality in HIV/Hepatitis C virus coinfected individuals. J Rockstroh, L Peters, V Soriano, P Reiss, A d'Arminio Monforte, M Beniowski, M Losso, O Kirk, B Kupfer, A Mocroft on behalf of the EuroSIDA Study Group. Oral 111 KB

3 Association between modifiable and non-modifiable risk factors and specific causes of death in the HAART era: Results from the D:A:D study. C Smith, R Weber, S Worm, A Phillips, R Thiebaut, N Friis-Møller, C Pradier, O Kirk, A d'Arminio Monforte, W El Sadr, P Reiss, J Lundgren, C Sabin on behalf of the D:A:D Study Group.Presentation 113 KB

4 Effect of Interleukin-2 on Clinical Outcomes in Patients with a CD4+ Cell Count of 300/mm3: Primary Results of the ESPRIT Study. Marcelo Losso. Oral

5 Effect of Interleukin-2 on Clinical Outcomes in Patients with CD4+ Cell Count 50 to 299/mm3: Primary Results of the SILCAAT Study. Yves Levy and SILCAAT Sci Committee. Oral

Posters

1 Hyaluronic Acid as a Prognostic Marker of Hepatic Coma and Liver-related Death in HIV/Viral Hepatitis Coinfected Patients. L Peters, A Mocroft, V Soriano, J Rockstroh, B Ledergerber, A Karlsson, B Knysz, C Pradier, K Zimler, JD Lundgren for the EuroSIDA study group.
Poster 139 KB

2 Mutation A376S in the RT connection domain is associated with an increased risk of virological failure to nevirapine- based therapy in NNRTI-naïve HIV-infected subjects in the EuroSIDA Study. R Parades, W Bannister, A Cozzi-Lepri, C Pou, R Bellido, J Bogner, P Gargalianos, D Bánhegyi, B Clotet, JD Lundgren and the EuroSIDA study group.
Poster 247 KB

3 Serious Fatal and Non Fatal Non-AIDS Defining Illnesses (non-ADI) in Europe. A. Mocroft, P Reiss, J Gasiorowski, B Ledergerber, A Chiesi, J Gatell, A Rakhmanova, MA Johnson, O Kirk, JD Lundgren for the EuroSIDA study group.
Poster 93 KB

4 Relationship between Current Level of Immunodeficiency and Non-AIDS malignancies. J Reekie, A Mocroft, F Engsis, A d'Arminio Monforte, A Wiercinska-Drapalo, P Domingo, F Antunes, N Clumeck, O Kirk, JD Lundgren for the EuroSIDA study group.
Poster 111 KB

5 Interruption of Antiretroviral Therapy and Changes in Hyaluronic Acid as Marker of Liver Fibrosis Progression in SMART Viral Hepatitis Coinfected Participants and Matched Controls. L Peters, J Neuhaus, A Mocroft, V Soriano, J Rockstroh, G Dore, M Puoti, E Tedaldi, B Clotet, B Kupfer, JD Lundgren, MB Klein for the INSIGHT SMART Study Group.
Poster 337 KB

6 Risk of extensive triple class virologic failure of the three original antiretroviral drug classes among people followed from therapy initiation with NNRTI or ritonavir-boosted PI regimens. R Lodwick on behalf of the PLATO II project team of COHERE.
Poster 159 KB

7 Impact of cART on Incidence and Prognosis of HIV-1-associated Non-Hodgkin-Lymphoma - European Multi-Cohort Study. J Bohlius, M Egger, on behalf of the COHERE study group.
Poster 517 KB

8 Antiretroviral Therapy (ART) Reinitiation and Hepatitis B Virus (HBV) Rebound among HIV – HBV Coinfected Patients following ART interruption in the SMART Study. V. Soriano. Poster

9 Does Treatment Interruption within the SMART trial lead to changes in hepatitis C virus load in HIV-/HCV-coinfected patients? J Rockstroh. Poster

10 Does Activation of Inflammatory and Coagulation Pathways Independently Predict the Development of Opportunistic Disease in Patients with HIV Infection? A Rodger. Poster

2008

The 9th International Congress on Drug Therapy in HIV Infection, Glasgow, November 2008

Oral presentations

1 Patterns of prior viral suppression on cART as predictors of future risk of viral rebound. J Reekie, A Mocroft, B Ledergerber, M Beniowski, B Clotet, J van Lunzen, A Chiesi, C Pradier, L Machala, JD Lundgren
Poster 90 KB

2 Opportunistic infections in immunocompromised but virologically suppressed HIV-1 infected patients. W Bannister, A Mocroft, O Kirk, P Reiss, A d´Arminio-Monforte, J Gatell, M Fischer, H Trocha, A Rakhmanova, and JD Lundgren.
Poster 110 KB

3 The rate of change of CD4 count (CD4 slopes) in patients with stable HIV viremia currently taking combination antiretroviral therapy or off all antiretrovirals. A Mocroft, AN Phillips, B Ledergerber, J Bogner, K Lacombe, A Wiercinska-Drapalo, P Reiss, O Kirk, JD Lundgren for the EuroSIDA study group.
Poster 99 KB

4 Predicting the short term risk of diabetes in HIV infected patients in the D:A:D cohort: The D:A:D study group. K Petoumenos, E Fontas, SW Worm, R Weber, S De Wit, M Bruyand, CA Sabin, P Reiss, W El-Sadr, A D´Arminio-Monforte, N Friis-Møller, JD Lundgren, M Law on behalf of the D:A:D study group.
Poster 152 KB

5 The relationship between an adverse effect of antiretroviral treatment and underlying risk in number needed to treat to harm - risk of myocardial infarction and abacavir use. J Kowalska, O Kirk, A Mocroft, L Høj, N Friis-Møller, P Reiss, JD Lundgren
Poster 249 KB

6 Poor clinical oputcome in HIV-infected patients coinfected with mycobacterium tuberculosis (TB) in Eastern Europe. The HIV/TB collaborative study. D Podlekareva, A Mocroft, F Post, V Riekstina, J Miro, H Furrer, M Bruyand, E Malashenkov, E Girardi, JJ Toibaro, J Cayla, R Miller, N Obel, A Skrahin, N Chentsova, JD Lundgren, O Kirk and the HIV/TB study group.
Poster 251 KB

Poster presentation

1 Are non-B subtypes less susceptible to antiretroviral drugs? - a bioinformatical approach to prediction on non-B subtype susceptibility. J Kjær, L Høj, N Friis-Møller, P Reiss, JD Lundgren
Poster 249 KB

XVII International AIDS Conference, Mexico City, August 2008

Oral presentations

1 Use of nucleos(t)ide reverse transcriptase inhibitors (NRTIs) and risk of myocardial infarction in HIV-infected patients enrolled in the SMART study. JD Lundgren and the SMART/INSIGHT and D:A:D Study Groups.
Slides 127 KB

2 TB and injecting drug use in Eastern Europe Clinical and Epidemiological Aspects and Implications for Public Health. D. Podlekareva
Slides 716 KB

Polish National Conference on HIV, Warsaw, June 2008

1 Risk of myocardial infarction attributable to abacavir: Analysis to assess the number needed to treat to harm. Justyna D. Kowalska, Ole Kirk, Amanda Mocroft, Jens D. Lundgren
Poster 239 KB

XVII International HIV Drug Resistance Workshop, Sitges, June 2008

Poster presentations

1 In silico identification of physiochemical properties at mutating positions relevant to reduced susceptibility to amprenavir. L Høj, J Kjær, O Winther, A Cozzi-Lepri and JD Lundgren.
Poster No.113 104 KB

2 The rate of accumulation of NNRTI-resistance in patients kept on a virologically failing regimen containing NNRTI: a EuroSIDA Study. A Cozzi-Lepri, B Clotet, R Paredes, J Kjær, AN Phillips, and JD Lundgren for the EuroSIDA study group.
Poster No.128 154 KB

3 Treatment-ermergent gag cleavage site mutations during virological failure of ritonavir-boosted protease-inhibitors. A Garcia- Diaz, Z Fox, UB Dragsted, J Kjær, N Clumeck, A Phillips, JD Lundgren and AM Geretti.
Poster 73

15th Conference on Retroviruses and Opportunistic Infections, Boston, February 2008
Poster presentations

1 The use and response to second combination antiretroviral therapy (cART) regimens in EuroSIDA. A Cozzi-Lepri, M Cunnington, A Lazzarin, B Clotet, B Knysz, P Gargalianos, C Katlama, A Karlsson, AN Phillips, J D Lundgren
Poster No. 797 129 KB

2 What frequency of monitoring is needed for health-care in a HIV-infected person?J Reekie, B Gazzard, H Sambatakou, A Chiesi, J van Lunzen, N Clumeck, O Kirk, A Mocroft, L Machala, J Lundgren
Poster No. 808 104 KB

3 Indicators of the use of health care interventions across Europe. D Podlekareva, J Reekie, A Rakhmanova, A Horban, A Mocroft, I Karpov, P Domingo, F Antunes, O Kirk, JD Lundgren and the EuroSIDA study group
Poster No. 811 157 KB

4 Do Thymidine Analogues, Abacavir, Didanosine and Lamivudine Contribute to the Risk of Myocardial Infarction (MI)?
Recent Use of Abacavir and Didanosine, but not of Thymidine Analogues, Is Associated with Risk of Myocardial Infarction.
Writing group: CA Sabin, SW Worm, R Weber, P Reiss, W El-Sadr, R Thiebaut, S De Wit, M Law, A D’Arminio Monforte, N Friis-Møller, O Kirk, C Pradier, S Collins, I Weller, AN Phillips, JD Lundgren on behalf of the D:A:D study group
Poster No. 957c 121 KB

5 Deterioration of renal function (DRF) associated with current level of immunodeficiency. O Kirk, A Mocroft, A d’Armino Monforte, A-BE Hansen, JM Gatell, S Caplinskas, G Fätkenheuer, P Reiss, E Vinogradova, JD Lundgren for the EuroSIDA study group.
Poster No. 971 133 KB

6 Characteristics and clinical outcome of patients with HIV-associated tuberculosis (HIV/TB) in Europe and Argentina. D Podlekareva, A Mocroft, A Panteleev, J Toibaro, A Rakhmanova, V Riekstina, H-J Furrer, O Suetnov, F Post, O Kirk and the HIV/TB Study Group
Poster No. 1000 197 KB

7 Hepatitis C virus (HCV) coinfection does not influence the CD4 cell recovery in HIV infected patients with maximum virologic suppression within the EuroSIDA cohort. L Peters, A Mocroft, V Soriano, J Rockstroh, P Aldins, M Losso, L Valerio, P Reiss, B Ledergerber, JD Lundgren for the EuroSIDA study group.
Poster No. 1069 102 KB

8 Hepatitis Virus Co-infections and Risk of Diabetes Mellitus (DM) and Myocardial Infarction (MI) in HIV-infected Persons: The D:A:D Study.R Weber, C Sabin, P Reiss, S De Wit, S Worm, M Law, F Dabis, A d'Arminio Monforte, E Fontas, J Lundgren
Poster No. 1082 82 KB

Oral presentations

1 Re-initiation of antiretroviral therapy (ART) in the CD4-guided ART interruption group in the SMART study lowers risk of opportunistic disease or death. W El-Sadr and the SMART study group
Abstract No. 36

2 Elevated levels of interleukin-6 and D-dimer are associated with an increased risk of death in patients with HIV. L Kuller and the SMART study group
Abstract No. 139

3 Age/sex-specific death rates in ART naïve patients with CD4 count above 350 cells/mm3 compared with the general population. R Lodwick, K Porter, C Sabin, B Ledergerber, A Cozzi-Lepri, P Khaykin, A Mocroft, L Jacobson, S de Wit, A Phillips on behalf of the Study Group on Death Rates at High CD4 Count in Antiretroviral Naive Patients
Abstract No.141

2007

11th European AIDS Conference (EACS), Madrid, October 2007

Posters

1 Diminished susceptibility to didanosine due to 184I/Vand thymidine analog mutations in isolates without major IAS-USA didanosine-specific and cross-resistant mutations.
J Kjær, A Cozzi-Lepri, Z Fox, and JD Lundgren
Poster P3.2/04 as pdf file 97 kb

2 Concordance between genotypic interpretation systems for predicting resistance to tipranavir/r and darunavir/r: results from the EuroSIDA study. Z Fox, A Cozzi-Lepri, B Clotet, J Kjaer, AN Phillips and JD Lundgren for the EuroSIDA study group
Poster P3.4/02 as pdf file 133 kb

3 Predicting the CD4 slope in patients starting cART after 1 January 1999
JD Lundgren, J Gatell, JR Bogner, K Lacombe, M Murphy, A Wiercinska-Drapalo, P Reiss, A Lazzarin, AN Phillips, A Mocroft for the EuroSIDA study group
Poster P6.11/02/BPD as pdf file 169 kb

4 Virological response to nucleos(t)ide analogues backbones initiated after virological
failure on thymidine analogues-containing treatments.
A Cozzi-Lepri, AN Phillips, B Clotet, C Katlama, A Castagna, A Karlsson, B Ledergerber, B Knysz, K Zilmer, O Kirk and JD Lundgren for the EuroSIDA study group
Poster P7.4/01 as pdf file 94 kb

5 Incidence of pancreatitis amongst HIV-positive individuals, and the association with triglycerides and antiretroviral use. CJ Smith, A Mocroft, CH Olsen, F Antunes, S Staszewski, P Domingo, J Weber, E Vinogradova, H Sambattakou, JP Viard, JD Lundgren and the EuroSIDA Study Group
Poster P9.10/02 as pdf file 92 kb

6 The EuroSIDA risk score : Separate prediction for AIDS or death. JD Lundgren, B Ledergerber, B Gazzard, D Banhegyi, M Mokras, D Turner, P Domingo, G Fatkenheuer, O Kirk, A Mocroft for the EuroSIDA study group
Poster P18.4/01 as pdf file 199 kb

Oral

1 Does diabetes mellitus (DM) confer a risk of coronary heart disease (CHD) equivalent to that of prior CHD in HIV-positive individuals? S Worm, S de Wit, R Weber, C Sabin, P Reiss, W El-Sadr, A D´arminio Monforte, O Kirk, E Fontas, F Dabis, M Law, J Lundgren, N Friis-Møller for the D:A:D Study group
Abstract No. PS2/6 slides

2 Does Hepatitis C virus (HCV) genotype or viral load predict the risk of all-cause mortality of HIV/HCV coinfection? JK Rockstroh, A Mocroft, P Reiss, A D`Arminio Monteforte, M Beniowski, C Pradier, K Zilmer, M Losso, O Kirk, L Peters, B Kupfer, V Soriano on behalf of the EuroSIDA Study Group
Abstract No. PS8/2 slides

3 Epidemiological and virological characteristics of chronic hepatitis C (HCV) within the EuroSIDA observational cohort. V Soriano, A Mocroft, B Ledergerber, B Knysz, S Chaplinskas, L Peters, A Karlsson, C Katlama, M Vogel, J Rockstroh, JD Lundgren for the EuroSIDA study group.
Abstract No. PS8/1 slides

4th IAS Conference on HIV Pathogenisis, Treatment and Prevention, Sydney, July 2007

Oral

1 Higher rate of antiretroviral therapy reinitiation among HIV-HBV coinfected patients in the episodic therapy arm of the SMART study. G Dore, V Soriano, J Neuhaus, L Peters, M Puoti, J Rockstroh, M Klein, E Tedaldi, A Mocroft, B Clotet, JD Lundgren; For the SMART study group and INSIGHT

2 Opportunistic disease and mortality in patients co-infected with hepatitis C virus (HCV) and/or hepatitis B virus (HBV) in the SMART (Strategic Management of Antiretroviral Therapy) study. E Tedaldi, M Puoti, J Neuhaus, L Peters, J Rockstroh, M Klein, G Dore, A Mocroft, V Soriano, B Clotet, JD Lundgren; For the SMART study group and INSIGHT

9th Intl Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Sydney July 2007

1 Does diabetes mellitus (DM) confer an equivalent risk of coronary heart disease (CHD) to pre-existing CHD in HIV-positive individuals? SW Worm, S De Wit, R Weber, CA Sabin, P Reiss, W El-Sadr, A D‘Arminio Monforte, O Kirk, E Fontas, F Dabis, MG Law, JD Lundgren and N Friis-Møller on behalf of the D:A:D study group
Abstract No 0-09

XVI International HIV Drug Resistance Workshop, Barbados, June 2007

1 Prediction of phenotypic susceptibility to the three major HIV drug classes from physiochemical properties of the primary enzymatic structure using artificial neural networks (ANNs). J Kjær, L Høj, Z Fox and JD Lundgren

Poster as pdf file 585 kb

2 Association between Resistance and CD4 Count Change in Patients on ART with Ongoing Viraemia. ZV Fox, AM Geretti, B Clotet, A Cozzi-Lepri, T Hill, H Green, CA Sabin, B Ledergerber, JD Lundgren and AN Phillips for the UK Collaborative Group on HIV Drug Resistance, EuroSIDA and UK CHIC Studies

Poster as pdf file 153 kb

3 Rate of accumulation of thymidine analogue mutations in patients left on virologically failing regimens containing zidovudine or stavudine. A Cozzi-Lepri, AN Phillips, J Martinez-Picado, A d’Arminio Monforte, C Katlama, A-B Eg Hansen, A Horban, J Bruun, B Clotet and J Lundgren for the EuroSIDA study group

Poster as pdf file 86 kb

4 Proof-of-Principle Evaluation of Predictive Performance for Therapy Outcome of Baseline Estimated Fitness and Genetic Barrier towards Resistance in a Clinical Cohort of HIV-1 Treated Patients. K Deforche, A Cozzi-Lepri, K Theys, B Clotet, R Camacho, J Kjaer, K Van Laethem, AN Phillips, Y Moreau, JD Lundgren and A-M Vandamme for the EuroSIDA study Group.

Poster as pdf file 155kb

5th European HIV Drug Resistance Workshop, Cascais, March, 2007

Poster

1 Prediction of phenotypic susceptibility to seven protease inhibitors from chemical and structural descriptors of the protease gene’s amino acid sequence using artificial neural networks. J Kjær, L Høj, Z Fox and JD Lundgren

Poster as pdf file 738 kb

14th Conference o­n Retroviruses and Opportunistic Infections, Los Angeles, February 2007

Oral

1 HIV-induced immunodeficiency and risk of fatal AIDS-defining and Non-AIDS-defining malignancies: Results from the D:A:D Study Group. A D´Arminio Monforte, D Abrams C Pradier R Weber, F Bonnet, S De Wit, N Friis-Møller, A Phillips, C Sabin, JD Lundgren, and the D:A:D Study Group.
Abstract No. 84

Posters

1 Predicting the risk of coronary heart disease (CHD) in HIV-infected patients: The D:A:D CHD risk equation. N Friis-Møller, R Thiébaut, P Reiss, W El-Sadr, R Weber, A D´Arminio Monforte, E Fontas, SW Worm, O Kirk, A Phillips, CA Sabin, JD Lundgren, M Law, and the D:A:D Study Group.

Poster 808 as pdf file 191 KB

2 Presence of the metabolic syndrome (MS) is not a better predictor of cardiovascular disease (CVD) that the sum of its components; Data from the D:A:D study. SW Worm, CA Sabin, P Reiss, W El-Sadr, A D´Arminio Monforte, C Pradier, R Thiebaut, M Law, M Rickenback, S de Wit, JD Lundgren, N Friis-Møller and the D:A:D Study Group

Poster 815 as pdf file 113 KB

3 Underutilization of recommended interventions for prevention of cardiovascular (CV) disease in HIV-infected patients with established CV disease or diabetes. CA Sabin, R Weber, F Dabis, P Reiss, S de Wit, W El-Sadr, A D´Arminio Monforte, M Law, O Kirk, SW Worm , N Friis-Møller, JD Lundgren, and the D:A:D Study Group.

Poster 816 as pdf file 118 KB

4 Detection of chronic renal failure (CRF) amon HIV-patients within the EuroSIDA Study. A Mocroft, O Kirk, J Gatell, P Reiss, P Gargalianos, K Zilmer, M Beniowski, JP Viard, S Staszewski, JD Lundgren for the EuroSIDA Study Group.

Poster 828 as pdf file 106 KB

5 Normalisation of CD4 count in HIV-infected patients with maximal virological suppression (<50 copies/ml) taking combination antiretroviral therapy. A Mocroft, AN Phillips, J Gatell, B Ledergerber, M Fisher, N Clumeck, M Losso, A Lazzarin, G Fätkenheuer, JD Lundgren for the EuroSIDA Study Group

Poster 519 as pdf file 100 KB

6 Predicted risk of coronary heart disease (CHD) with Tipranavir exposure compared to conventional PI in the RESIST trial. N Friis-Møller, M Kraft, H Valdez, D Hall, and JD Lundgren.

Poster 809 as pdf file 122 KB

2006

The 8th International Congress on Drug Therapy in HIV Infection, Glasgow, November 2006

Oral Presentations

1 Relationship between use of stavudine and diabetes mellitus. S. de Wit, CA Sabin, R Weber, SW Worm, P Reiss, R Thiebaut, W El-Sadr, A D´Arminio Monforte, E Fontas, MG Law, AN Phillips, N Friis-Møller, JD Lundgren for the DAD study Group.
Slides as pdf file 60 kb>

2 Effect of interventions to improve dyslipidaemia. M de Valk, N Friis-Møller, CA Sabin, F Dabis, A d´Arminio Monforte, R Weber, S Worm, W El-Sadr, S de Wit, C Pradier, O Kirk, M Law, AN Phillips, JD Lundgren, P Reiss for the DAD study group
Slides as pdf file 96 kb

3 Final safety and efficacy analysis of a randomised pilot study evaluating early versus late switch from efavirenz to nevirapine as part of HAART: the BI Switch Study. M Youle, U B Dragsted, D Podlekareva, C Smith, A Caroll, F Turner, M Johnson

Poster Presentations

1 Comparison of single and boosted-protease-inhibitor (PI) versus non-nucleoside reverse transcriptase inhibitor (NNRTI) containing regimens in previously antiretroviral naïve patients. A Mocroft, O Kirk, A Horban, N CLumeck, HJ Stellbrink, A d´Arminio, K Zilmer, J Gatell, AN Phillips, JD Lundgren for the EuroSIDA study group.
Poster as pdf file 138 kb

2 Abacavir hypersensitivity reaction in EuroSIDA. W Bannister, N Friis-Møller, A Mocroft, JP Viard, J van Lunzen, O Kirk, P Garglianos, D Banhegyi, A Chiesi, J Lundgren for the EuroSIDA study group.
Poster as pdf file 673 kb

3 The Metabolic Syndrome at baseline in the D:A:D Study. S Worm, C Sabin, W El-Sadr, P Reiss, A Monforte, M Rickenbach, R Thiebaut, S de Wit, E Fontas, M Law, O Kirk, J Lundgren, N Friis-Møller for the DAD study
Poster as pdf file 129 kb

The XVI International AIDS Conference, Toronto, August 2006

Oral Presentations

1 Progression of HIV-related disease or death (POD) in the randomised SMART study:why was the risk of POD greater in the CD4 guided ((re)-initiate ART at CD4<250 cells/µL) drug conservation (DC) vs the virological suppression(VS) arm? Jens D. Lundgren on behalf of the SMART study group.

2 Risk of discontinuation of nevirapine due to toxicitites in antiretroviral naive and experienced patients with high and low CD4 counts. A Mocroft, J Rockstroh, J Gasiorowski, F Antunes, G Panos, A d´Arminio Monforte, A Rakhmanova,, AN Phillips, JD Lundgren for the EuroSIDA study group.
Slides as pdf file 153 KB

3 All naïve patients are not equal: when and how to start HAART. JD Lundgren
Link to session

Posters

1 The ability of four genotypic resistance algorithmis for predicting HIV-RNA responses 4-24 weeks after initiating a boosted PI-containing regimen. Z Fox, J Kjær, AN Phillips, L Ruiz, B Clotet, S Staszewski, C Holkmann Olsen, A Horban, B Ledergerber, JD Lundgren for the EuroSIDA study group.
Poster as pdf file 137 KB

2 Genotypic resistance profile before initiation of cART and association with virological and clinical outcome in EuroSIDA. WP Bannister, AN Phillips, B Clotet, P Reiss, B Ledergerber, A Lazzarin, C Katlama, A Cozzi-Lepri, L Ruiz, JD Lundgren for the EuroSIDA study group.
Poster as pdf file 85 KB

3 Short term clinical disease progression in HIV-1 positive patients taking combination antiretroviral therapy: The EuroSIDA risk-score. A Mocroft, B Ledergerber, K Zilmer, O Kirk, B Hirschel, JP Viard, P Reiss, P Francioli, A Lazzarin, L Machala, AN Phillips, JD Lundgren for the EuroSIDA study and the Swiss HIV Cohort study.
Poster as pdf file 759 KB

4th European Drug Resistance Workshop, Monte Carlo, March 2006

1 The ability of four genotypic resistance algorithms to predict HIV-RNA responses to boosted PI-containing regimens after 4 and 12 weeks follow-up. Z Fox, M Gisslen, B Gazzard, J Kjær, H Nielsen, M Youle, I Cassetti, AN Phillips, UB Dragsted, and JD Lundgren on behalf of the MaxCmin1, MaxCmin2 and COLATE trial groups
Poster as pdf-file 636 KB

13th Conference o­n Retroviruses and Opportunistic Infections, Denver, February 2006

Oral presentation

1 Exposure to PI and NNRTI and risk of myocardial infaction: Results from the D:A:D Study. N Friis-Møller, P Reiss, W El-Sadr, A D´Arminio Monforte, R Thiebaut, S De Wit, R Weber, E Fontas, M Law, A Phillips, O Kirk, CA Sabin, JD Lundgren, and the D:A:D Study group

Posters

1 Mutation at reverse transcriptase codon 214 is antagonist to thymidine analogue mutations type 2 profiles and predicts virological response to thymidine analogue-containing cART regimens only if TAM type 1 profiles concomitantly detected. A Cozzi-Lepri, L Ruiz, F Ceccherini-Silberstein, A Mocroft, A Phillips, J Gatell, B Ledergerber, P Reiss, B Clotet, JD Lundgren and the EuroSIDA Study group.
Poster as pdf file 966 KB

2 Factors associated with the development of opportunistic infections in HIV-1-infected adults with high CD4 cell counts in the EuroSIDA study. D Podlekareva, U Dragsted, A Mocroft, B Ledergerber, M Beniowski, A Lazzarin, J Weber, N Clumeck, A Phillips, JD Lundgren and the EuroSIDA Study group.
Poster as pdf file 76 KB

3 Exposure to antiretroviral therapy and the risk of liver-related death: Is there an association? Results from the D:A:D Study. R Weber, C Sabin, N Friis-Møller, A D'Arminio Monforte, P Reiss, W El-Sadr, F Dabis, M Law, C Pradier, S De Wit, O Kirk, A Phillips, JD. Lundgren; On behalf of the D:A:D Study Group
Poster as pdf file100 KB